New Protocol: Cemiplimab with Chemotherapy in NSCLC
Study
Double-blind, placebo-controlled, phase 3 study
|
|
Untreated advanced or metastatic NSCLC
|
|
Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154))
|
|
Efficacy
mOS : 21.9 vs. 13.0 mos (HR = 0.71, p= 0.014)
|
mPFS: 8.2 vs. 5.0 mos (HR = 0.56, p < 0.001)
|
ORR: 43.3% vs. 22.7% (OR:2.68)
|
CR: 2.7% vs. 0%
|
|
Safety
Any grade AEs: 95.8% vs 94.1%
|
Grade ≥3 AEs: anemia (9.9% vs. 6.5%); neutropenia (5.9% vs 5.8%)
|
|
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Reviewed by Elvin Chalabiyev, MD on Jan 10, 2023